Justine Guillot1, Denis Lebel2, Hélène Roy2, Philippe Ovetchkine3, Jean-François Bussières4. 1. Pharmacy Practice Research Unit, CHU Sainte-Justine, Montréal, Québec, Canada. 2. Pharmacy Practice Research Unit, CHU Sainte-Justine, Montréal, Québec, Canada ; Pharmacy Department, CHU Sainte-Justine, Montréal, Québec, Canada. 3. Pediatrics Department, CHU Sainte-Justine, Montréal, Québec, Canada. 4. Pharmacy Practice Research Unit, CHU Sainte-Justine, Montréal, Québec, Canada ; Pharmacy Department, CHU Sainte-Justine, Montréal, Québec, Canada ; Faculty of Pharmacy, Université de Montréal, Montréal, Québec, Canada.
Abstract
OBJECTIVES: The objective was to describe antifungal drug use by using the number of defined daily doses (DDD)/1000 patient-days per antifungal, the number of days of therapy (DOT)/1000 patient-days per antifungal, and the mean dose in mg/kg/day per antifungal during a 10-year period. METHODS: Retrospective, cross-sectional, descriptive study, in a mother-child university hospital center, with 400 pediatric beds and 100 obstetrics-gynecology beds. All inpatients who received 1 of the 7 authorized antifungals on the institution's local formulary in 2000-2001, 2005-2006, or 2010-2011 were included. Prescriptions for emergency department and outpatient clinics were excluded. The data were extracted from the patients' computerized medication profiles linked to patient admission, discharge, and transfer data. The DDD, DOT, and the mean dose in mg/kg/day were calculated for each antifungal and overall. RESULTS: There was a 2.97-fold increase in the overall number of DDD/1000 patient-days, from 14.8 in 2000-2001 to 37.5 in 2005-2006 and 43.9 in 2010-2011. There was a 2.97-fold increase in the overall number of DOT/1000 patient-days, from 22.8 in 2000-2001 to 50.3 in 2005-2006 and 67.8 in 2010-2011. CONCLUSIONS: It can be difficult to compare the use of antifungal drugs among institutions, owing to numerous factors, but it gives an idea about the consumption outside the studied center. Moreover, these ratios help to evaluate the use of antifungals within a same institution. These data could be correlated among others, with resistance patterns, in order to improve our daily practice concerning antifungal prescription.
OBJECTIVES: The objective was to describe antifungal drug use by using the number of defined daily doses (DDD)/1000 patient-days per antifungal, the number of days of therapy (DOT)/1000 patient-days per antifungal, and the mean dose in mg/kg/day per antifungal during a 10-year period. METHODS: Retrospective, cross-sectional, descriptive study, in a mother-child university hospital center, with 400 pediatric beds and 100 obstetrics-gynecology beds. All inpatients who received 1 of the 7 authorized antifungals on the institution's local formulary in 2000-2001, 2005-2006, or 2010-2011 were included. Prescriptions for emergency department and outpatient clinics were excluded. The data were extracted from the patients' computerized medication profiles linked to patient admission, discharge, and transfer data. The DDD, DOT, and the mean dose in mg/kg/day were calculated for each antifungal and overall. RESULTS: There was a 2.97-fold increase in the overall number of DDD/1000 patient-days, from 14.8 in 2000-2001 to 37.5 in 2005-2006 and 43.9 in 2010-2011. There was a 2.97-fold increase in the overall number of DOT/1000 patient-days, from 22.8 in 2000-2001 to 50.3 in 2005-2006 and 67.8 in 2010-2011. CONCLUSIONS: It can be difficult to compare the use of antifungal drugs among institutions, owing to numerous factors, but it gives an idea about the consumption outside the studied center. Moreover, these ratios help to evaluate the use of antifungals within a same institution. These data could be correlated among others, with resistance patterns, in order to improve our daily practice concerning antifungal prescription.
Entities:
Keywords:
antifungal agents; antimicrobial stewardship; days of therapy; defined daily dose; drug utilization
Authors: Alexander Imhof; S Arunmozhi Balajee; David N Fredricks; Janet A Englund; Kieren A Marr Journal: Clin Infect Dis Date: 2004-08-13 Impact factor: 9.079
Authors: Alberto Fica C; Angela Cabello M; Chrystal Juliet L; Priscilla Prado D; Luis Bavestrello F Journal: Rev Chilena Infectol Date: 2009-01-29 Impact factor: 0.520
Authors: Paul P Cook; Paul G Catrou; John D Christie; Pamela D Young; Ronald E Polk Journal: J Antimicrob Chemother Date: 2004-03-24 Impact factor: 5.790